nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—Ethinyl Estradiol—prostate cancer	0.207	1	CrCtD
Levonorgestrel—polycystic ovary syndrome—Ethinyl Estradiol—prostate cancer	0.17	1	CpDpCtD
Levonorgestrel—SRD5A1—prostate cancer	0.0751	0.449	CbGaD
Levonorgestrel—SHBG—prostate cancer	0.0254	0.152	CbGaD
Levonorgestrel—AR—prostate cancer	0.0223	0.133	CbGaD
Levonorgestrel—AR—Bicalutamide—prostate cancer	0.0212	0.122	CbGbCtD
Levonorgestrel—AR—Nilutamide—prostate cancer	0.0212	0.122	CbGbCtD
Levonorgestrel—CYP19A1—prostate cancer	0.0187	0.111	CbGaD
Levonorgestrel—AR—Flutamide—prostate cancer	0.0175	0.101	CbGbCtD
Levonorgestrel—ESR1—prostate cancer	0.0172	0.103	CbGaD
Levonorgestrel—ESR1—Estramustine—prostate cancer	0.017	0.0983	CbGbCtD
Levonorgestrel—SHBG—Estrone—prostate cancer	0.0152	0.0876	CbGbCtD
Levonorgestrel—SHBG—Ethinyl Estradiol—prostate cancer	0.0135	0.0781	CbGbCtD
Levonorgestrel—Nandrolone decanoate—Estradiol valerate/Dienogest—prostate cancer	0.0127	0.0698	CrCrCtD
Levonorgestrel—Nandrolone phenpropionate—Estradiol valerate/Dienogest—prostate cancer	0.0127	0.0698	CrCrCtD
Levonorgestrel—ESR1—Estrone—prostate cancer	0.011	0.0633	CbGbCtD
Levonorgestrel—Testosterone—Abiraterone—prostate cancer	0.0105	0.058	CrCrCtD
Levonorgestrel—ESR1—Ethinyl Estradiol—prostate cancer	0.00977	0.0565	CbGbCtD
Levonorgestrel—Ethinyl Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.00958	0.0528	CrCrCtD
Levonorgestrel—CYP3A4—prostate cancer	0.00876	0.0523	CbGaD
Levonorgestrel—SHBG—Estradiol—prostate cancer	0.00871	0.0503	CbGbCtD
Levonorgestrel—Mestranol—Estramustine—prostate cancer	0.00855	0.0471	CrCrCtD
Levonorgestrel—Quinestrol—Estramustine—prostate cancer	0.00855	0.0471	CrCrCtD
Levonorgestrel—Ethinyl Estradiol—Estramustine—prostate cancer	0.00815	0.0449	CrCrCtD
Levonorgestrel—AR—Estradiol—prostate cancer	0.00728	0.0421	CbGbCtD
Levonorgestrel—ESR1—Conjugated Estrogens—prostate cancer	0.00717	0.0414	CbGbCtD
Levonorgestrel—Mestranol—Estrone—prostate cancer	0.00679	0.0374	CrCrCtD
Levonorgestrel—Quinestrol—Estrone—prostate cancer	0.00679	0.0374	CrCrCtD
Levonorgestrel—Desogestrel—Ethinyl Estradiol—prostate cancer	0.00678	0.0374	CrCrCtD
Levonorgestrel—Ethinyl Estradiol—Estrone—prostate cancer	0.00647	0.0357	CrCrCtD
Levonorgestrel—ESR1—Estradiol—prostate cancer	0.0063	0.0364	CbGbCtD
Levonorgestrel—Mestranol—Conjugated Estrogens—prostate cancer	0.00598	0.033	CrCrCtD
Levonorgestrel—Quinestrol—Conjugated Estrogens—prostate cancer	0.00598	0.033	CrCrCtD
Levonorgestrel—Testosterone Propionate—Estradiol valerate/Dienogest—prostate cancer	0.00592	0.0327	CrCrCtD
Levonorgestrel—Ethinyl Estradiol—Conjugated Estrogens—prostate cancer	0.0057	0.0314	CrCrCtD
Levonorgestrel—Etonogestrel—Ethinyl Estradiol—prostate cancer	0.00559	0.0308	CrCrCtD
Levonorgestrel—Norelgestromin—Ethinyl Estradiol—prostate cancer	0.00529	0.0292	CrCrCtD
Levonorgestrel—Quinestrol—Estradiol—prostate cancer	0.00515	0.0284	CrCrCtD
Levonorgestrel—Mestranol—Estradiol—prostate cancer	0.00515	0.0284	CrCrCtD
Levonorgestrel—Quinestrol—Ethinyl Estradiol—prostate cancer	0.00502	0.0277	CrCrCtD
Levonorgestrel—Mestranol—Ethinyl Estradiol—prostate cancer	0.00502	0.0277	CrCrCtD
Levonorgestrel—Ethinyl Estradiol—Estradiol—prostate cancer	0.0049	0.027	CrCrCtD
Levonorgestrel—Testosterone—Estramustine—prostate cancer	0.00437	0.0241	CrCrCtD
Levonorgestrel—Danazol—Ethinyl Estradiol—prostate cancer	0.00404	0.0223	CrCrCtD
Levonorgestrel—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00358	0.0207	CbGbCtD
Levonorgestrel—Norethindrone—Ethinyl Estradiol—prostate cancer	0.00352	0.0194	CrCrCtD
Levonorgestrel—Testosterone—Estrone—prostate cancer	0.00347	0.0191	CrCrCtD
Levonorgestrel—Methyltestosterone—Ethinyl Estradiol—prostate cancer	0.00289	0.0159	CrCrCtD
Levonorgestrel—Testosterone—Estradiol—prostate cancer	0.00263	0.0145	CrCrCtD
Levonorgestrel—CYP3A4—Bicalutamide—prostate cancer	0.00188	0.0109	CbGbCtD
Levonorgestrel—CYP3A4—Estramustine—prostate cancer	0.00175	0.0101	CbGbCtD
Levonorgestrel—SHBG—semen—prostate cancer	0.00166	0.127	CbGeAlD
Levonorgestrel—CYP3A4—Flutamide—prostate cancer	0.00156	0.009	CbGbCtD
Levonorgestrel—CYP3A4—Abiraterone—prostate cancer	0.00156	0.009	CbGbCtD
Levonorgestrel—Danazol—Prednisone—prostate cancer	0.00142	0.00783	CrCrCtD
Levonorgestrel—CYP19A1—semen—prostate cancer	0.00134	0.103	CbGeAlD
Levonorgestrel—AR—penis—prostate cancer	0.00125	0.0953	CbGeAlD
Levonorgestrel—AR—semen—prostate cancer	0.00119	0.0909	CbGeAlD
Levonorgestrel—CYP3A4—Cabazitaxel—prostate cancer	0.00115	0.00666	CbGbCtD
Levonorgestrel—SRD5A1—prostate gland—prostate cancer	0.00114	0.0871	CbGeAlD
Levonorgestrel—CYP3A4—Estrone—prostate cancer	0.00113	0.00651	CbGbCtD
Levonorgestrel—Methyltestosterone—Prednisone—prostate cancer	0.00101	0.00559	CrCrCtD
Levonorgestrel—CYP3A4—Ethinyl Estradiol—prostate cancer	0.001	0.0058	CbGbCtD
Levonorgestrel—Hydrocortisone—Prednisone—prostate cancer	0.000848	0.00467	CrCrCtD
Levonorgestrel—SRD5A1—renal system—prostate cancer	0.000778	0.0594	CbGeAlD
Levonorgestrel—CYP3A4—Conjugated Estrogens—prostate cancer	0.000737	0.00426	CbGbCtD
Levonorgestrel—CYP3A4—Mitoxantrone—prostate cancer	0.00067	0.00387	CbGbCtD
Levonorgestrel—CYP3A4—Estradiol—prostate cancer	0.000647	0.00374	CbGbCtD
Levonorgestrel—CYP3A4—Prednisone—prostate cancer	0.000556	0.00321	CbGbCtD
Levonorgestrel—SRD5A1—testis—prostate cancer	0.000503	0.0384	CbGeAlD
Levonorgestrel—CYP3A4—urine—prostate cancer	0.000455	0.0347	CbGeAlD
Levonorgestrel—CYP3A4—Etoposide—prostate cancer	0.000422	0.00244	CbGbCtD
Levonorgestrel—SHBG—prostate gland—prostate cancer	0.000416	0.0317	CbGeAlD
Levonorgestrel—CYP3A4—Docetaxel—prostate cancer	0.000386	0.00223	CbGbCtD
Levonorgestrel—PGR—prostate gland—prostate cancer	0.000374	0.0286	CbGeAlD
Levonorgestrel—CYP19A1—prostate gland—prostate cancer	0.000337	0.0257	CbGeAlD
Levonorgestrel—AR—prostate gland—prostate cancer	0.000298	0.0228	CbGeAlD
Levonorgestrel—ESR1—prostate gland—prostate cancer	0.000293	0.0224	CbGeAlD
Levonorgestrel—CYP3A4—Doxorubicin—prostate cancer	0.000288	0.00166	CbGbCtD
Levonorgestrel—PGR—epithelium—prostate cancer	0.000275	0.021	CbGeAlD
Levonorgestrel—AR—seminal vesicle—prostate cancer	0.000252	0.0193	CbGeAlD
Levonorgestrel—AR—epithelium—prostate cancer	0.000219	0.0167	CbGeAlD
Levonorgestrel—ESR1—epithelium—prostate cancer	0.000215	0.0164	CbGeAlD
Levonorgestrel—SHBG—bone marrow—prostate cancer	0.000214	0.0164	CbGeAlD
Levonorgestrel—AR—renal system—prostate cancer	0.000203	0.0155	CbGeAlD
Levonorgestrel—AR—urethra—prostate cancer	0.0002	0.0152	CbGeAlD
Levonorgestrel—ESR1—renal system—prostate cancer	0.0002	0.0152	CbGeAlD
Levonorgestrel—SHBG—testis—prostate cancer	0.000183	0.014	CbGeAlD
Levonorgestrel—PGR—testis—prostate cancer	0.000165	0.0126	CbGeAlD
Levonorgestrel—CYP19A1—testis—prostate cancer	0.000148	0.0113	CbGeAlD
Levonorgestrel—AR—testis—prostate cancer	0.000131	0.01	CbGeAlD
Levonorgestrel—ESR1—testis—prostate cancer	0.000129	0.00985	CbGeAlD
Levonorgestrel—PGR—lymph node—prostate cancer	0.00012	0.00913	CbGeAlD
Levonorgestrel—CYP3A4—renal system—prostate cancer	0.000111	0.0085	CbGeAlD
Levonorgestrel—CYP19A1—lymph node—prostate cancer	0.000108	0.00821	CbGeAlD
Levonorgestrel—AR—lymph node—prostate cancer	9.53e-05	0.00727	CbGeAlD
Levonorgestrel—ESR1—lymph node—prostate cancer	9.35e-05	0.00714	CbGeAlD
Levonorgestrel—Ethinyl Estradiol—AOX1—prostate cancer	6.42e-05	0.046	CrCbGaD
Levonorgestrel—Desogestrel—SHBG—prostate cancer	4.92e-05	0.0353	CrCbGaD
Levonorgestrel—Nandrolone phenpropionate—AR—prostate cancer	4.9e-05	0.0352	CrCbGaD
Levonorgestrel—Quinestrol—ESR1—prostate cancer	4.44e-05	0.0319	CrCbGaD
Levonorgestrel—Gestodene—CYP3A5—prostate cancer	4.25e-05	0.0305	CrCbGaD
Levonorgestrel—Testosterone Propionate—CYP17A1—prostate cancer	4.18e-05	0.03	CrCbGaD
Levonorgestrel—Hydrocortisone—ANXA1—prostate cancer	4.1e-05	0.0294	CrCbGaD
Levonorgestrel—Nandrolone phenpropionate—CYP19A1—prostate cancer	4.1e-05	0.0294	CrCbGaD
Levonorgestrel—Testosterone—CYP3A43—prostate cancer	4e-05	0.0287	CrCbGaD
Levonorgestrel—Etonogestrel—SHBG—prostate cancer	3.98e-05	0.0286	CrCbGaD
Levonorgestrel—Nandrolone decanoate—AR—prostate cancer	3.72e-05	0.0266	CrCbGaD
Levonorgestrel—Ethynodiol—ESR1—prostate cancer	3.66e-05	0.0262	CrCbGaD
Levonorgestrel—Allylestrenol—ESR1—prostate cancer	3.45e-05	0.0248	CrCbGaD
Levonorgestrel—Testosterone Propionate—COMT—prostate cancer	3.41e-05	0.0244	CrCbGaD
Levonorgestrel—Mestranol—ESR1—prostate cancer	3.37e-05	0.0241	CrCbGaD
Levonorgestrel—Desogestrel—ESR1—prostate cancer	3.32e-05	0.0238	CrCbGaD
Levonorgestrel—Norgestimate—ESR1—prostate cancer	3.11e-05	0.0223	CrCbGaD
Levonorgestrel—Nandrolone decanoate—CYP19A1—prostate cancer	3.11e-05	0.0223	CrCbGaD
Levonorgestrel—Etonogestrel—ESR1—prostate cancer	2.69e-05	0.0193	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—ESR2—prostate cancer	2.6e-05	0.0187	CrCbGaD
Levonorgestrel—Danazol—SHBG—prostate cancer	2.57e-05	0.0184	CrCbGaD
Levonorgestrel—Testosterone Propionate—AR—prostate cancer	2.54e-05	0.0182	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—SHBG—prostate cancer	2.38e-05	0.017	CrCbGaD
Levonorgestrel—Norethindrone—SHBG—prostate cancer	2.28e-05	0.0164	CrCbGaD
Levonorgestrel—Danazol—AR—prostate cancer	2.25e-05	0.0161	CrCbGaD
Levonorgestrel—Methyltestosterone—SHBG—prostate cancer	2.17e-05	0.0156	CrCbGaD
Levonorgestrel—Progesterone—CYP17A1—prostate cancer	1.92e-05	0.0138	CrCbGaD
Levonorgestrel—Methyltestosterone—AR—prostate cancer	1.9e-05	0.0136	CrCbGaD
Levonorgestrel—Danazol—CYP19A1—prostate cancer	1.88e-05	0.0135	CrCbGaD
Levonorgestrel—Progesterone—SLC22A3—prostate cancer	1.83e-05	0.0131	CrCbGaD
Levonorgestrel—Norethindrone—CYP3A5—prostate cancer	1.82e-05	0.013	CrCbGaD
Levonorgestrel—Allylestrenol—CYP3A4—prostate cancer	1.76e-05	0.0126	CrCbGaD
Levonorgestrel—Danazol—ESR1—prostate cancer	1.73e-05	0.0124	CrCbGaD
Levonorgestrel—Testosterone—SLC22A3—prostate cancer	1.73e-05	0.0124	CrCbGaD
Levonorgestrel—Hydrocortisone—SHBG—prostate cancer	1.63e-05	0.0117	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—ESR1—prostate cancer	1.6e-05	0.0115	CrCbGaD
Levonorgestrel—Methyltestosterone—CYP19A1—prostate cancer	1.59e-05	0.0114	CrCbGaD
Levonorgestrel—Etonogestrel—CYP3A4—prostate cancer	1.37e-05	0.00985	CrCbGaD
Levonorgestrel—Progesterone—CYP1B1—prostate cancer	1.33e-05	0.00955	CrCbGaD
Levonorgestrel—Progesterone—SHBG—prostate cancer	1.33e-05	0.00955	CrCbGaD
Levonorgestrel—Progesterone—SLC22A1—prostate cancer	1.31e-05	0.00942	CrCbGaD
Levonorgestrel—Hydrocortisone—CYP3A5—prostate cancer	1.3e-05	0.00933	CrCbGaD
Levonorgestrel—Testosterone—SHBG—prostate cancer	1.26e-05	0.00902	CrCbGaD
Levonorgestrel—Testosterone—CYP1B1—prostate cancer	1.26e-05	0.00902	CrCbGaD
Levonorgestrel—Testosterone—SLC22A1—prostate cancer	1.24e-05	0.00891	CrCbGaD
Levonorgestrel—Norethindrone—CYP2C19—prostate cancer	1.24e-05	0.00888	CrCbGaD
Levonorgestrel—Progesterone—AR—prostate cancer	1.17e-05	0.00837	CrCbGaD
Levonorgestrel—Testosterone—AR—prostate cancer	1.1e-05	0.00791	CrCbGaD
Levonorgestrel—Progesterone—CYP3A5—prostate cancer	1.06e-05	0.0076	CrCbGaD
Levonorgestrel—Progesterone—CYP2A6—prostate cancer	1.03e-05	0.00736	CrCbGaD
Levonorgestrel—Testosterone—CYP3A5—prostate cancer	1e-05	0.00719	CrCbGaD
Levonorgestrel—Hydrocortisone—NR3C1—prostate cancer	9.72e-06	0.00697	CrCbGaD
Levonorgestrel—Testosterone—CYP19A1—prostate cancer	9.23e-06	0.00662	CrCbGaD
Levonorgestrel—Progesterone—ESR1—prostate cancer	8.99e-06	0.00645	CrCbGaD
Levonorgestrel—Danazol—CYP3A4—prostate cancer	8.85e-06	0.00635	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—CYP3A4—prostate cancer	8.19e-06	0.00587	CrCbGaD
Levonorgestrel—Progesterone—NR3C1—prostate cancer	7.91e-06	0.00568	CrCbGaD
Levonorgestrel—Norethindrone—CYP3A4—prostate cancer	7.87e-06	0.00565	CrCbGaD
Levonorgestrel—Methyltestosterone—CYP3A4—prostate cancer	7.48e-06	0.00536	CrCbGaD
Levonorgestrel—Progesterone—CYP2C19—prostate cancer	7.21e-06	0.00517	CrCbGaD
Levonorgestrel—Progesterone—CYP1A1—prostate cancer	7.19e-06	0.00515	CrCbGaD
Levonorgestrel—Infestation—Doxorubicin—prostate cancer	7.01e-06	0.000126	CcSEcCtD
Levonorgestrel—Dermatitis—Estradiol—prostate cancer	7e-06	0.000126	CcSEcCtD
Levonorgestrel—Anaemia—Prednisone—prostate cancer	6.99e-06	0.000126	CcSEcCtD
Levonorgestrel—Headache—Estradiol—prostate cancer	6.96e-06	0.000125	CcSEcCtD
Levonorgestrel—Skin disorder—Docetaxel—prostate cancer	6.96e-06	0.000125	CcSEcCtD
Levonorgestrel—Oedema—Capecitabine—prostate cancer	6.93e-06	0.000125	CcSEcCtD
Levonorgestrel—Angioedema—Prednisone—prostate cancer	6.91e-06	0.000124	CcSEcCtD
Levonorgestrel—Infection—Capecitabine—prostate cancer	6.89e-06	0.000124	CcSEcCtD
Levonorgestrel—Urticaria—Etoposide—prostate cancer	6.85e-06	0.000123	CcSEcCtD
Levonorgestrel—Haemoglobin—Epirubicin—prostate cancer	6.83e-06	0.000123	CcSEcCtD
Levonorgestrel—Anorexia—Docetaxel—prostate cancer	6.83e-06	0.000123	CcSEcCtD
Levonorgestrel—Shock—Capecitabine—prostate cancer	6.82e-06	0.000123	CcSEcCtD
Levonorgestrel—Testosterone—CYP2C19—prostate cancer	6.82e-06	0.00489	CrCbGaD
Levonorgestrel—Rhinitis—Epirubicin—prostate cancer	6.82e-06	0.000123	CcSEcCtD
Levonorgestrel—Body temperature increased—Etoposide—prostate cancer	6.81e-06	0.000123	CcSEcCtD
Levonorgestrel—Abdominal pain—Etoposide—prostate cancer	6.81e-06	0.000123	CcSEcCtD
Levonorgestrel—Urinary tract infection—Doxorubicin—prostate cancer	6.81e-06	0.000123	CcSEcCtD
Levonorgestrel—Nervous system disorder—Capecitabine—prostate cancer	6.8e-06	0.000122	CcSEcCtD
Levonorgestrel—Vertigo—Prednisone—prostate cancer	6.8e-06	0.000122	CcSEcCtD
Levonorgestrel—Haemorrhage—Epirubicin—prostate cancer	6.8e-06	0.000122	CcSEcCtD
Levonorgestrel—Testosterone—CYP1A1—prostate cancer	6.79e-06	0.00487	CrCbGaD
Levonorgestrel—Syncope—Prednisone—prostate cancer	6.79e-06	0.000122	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Epirubicin—prostate cancer	6.76e-06	0.000122	CcSEcCtD
Levonorgestrel—Pharyngitis—Epirubicin—prostate cancer	6.75e-06	0.000121	CcSEcCtD
Levonorgestrel—Skin disorder—Capecitabine—prostate cancer	6.73e-06	0.000121	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Epirubicin—prostate cancer	6.71e-06	0.000121	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Capecitabine—prostate cancer	6.7e-06	0.000121	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Epirubicin—prostate cancer	6.68e-06	0.00012	CcSEcCtD
Levonorgestrel—Urethral disorder—Epirubicin—prostate cancer	6.66e-06	0.00012	CcSEcCtD
Levonorgestrel—Loss of consciousness—Prednisone—prostate cancer	6.65e-06	0.00012	CcSEcCtD
Levonorgestrel—Anorexia—Capecitabine—prostate cancer	6.61e-06	0.000119	CcSEcCtD
Levonorgestrel—Nausea—Estradiol—prostate cancer	6.6e-06	0.000119	CcSEcCtD
Levonorgestrel—Vomiting—Mitoxantrone—prostate cancer	6.59e-06	0.000119	CcSEcCtD
Levonorgestrel—Sinusitis—Doxorubicin—prostate cancer	6.57e-06	0.000118	CcSEcCtD
Levonorgestrel—Visual impairment—Epirubicin—prostate cancer	6.55e-06	0.000118	CcSEcCtD
Levonorgestrel—Hypertension—Prednisone—prostate cancer	6.53e-06	0.000118	CcSEcCtD
Levonorgestrel—Rash—Mitoxantrone—prostate cancer	6.53e-06	0.000118	CcSEcCtD
Levonorgestrel—Dermatitis—Mitoxantrone—prostate cancer	6.53e-06	0.000117	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Docetaxel—prostate cancer	6.52e-06	0.000117	CcSEcCtD
Levonorgestrel—Headache—Mitoxantrone—prostate cancer	6.49e-06	0.000117	CcSEcCtD
Levonorgestrel—Insomnia—Docetaxel—prostate cancer	6.48e-06	0.000117	CcSEcCtD
Levonorgestrel—Myalgia—Prednisone—prostate cancer	6.44e-06	0.000116	CcSEcCtD
Levonorgestrel—Erythema multiforme—Epirubicin—prostate cancer	6.43e-06	0.000116	CcSEcCtD
Levonorgestrel—Anxiety—Prednisone—prostate cancer	6.42e-06	0.000116	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	6.4e-06	0.000115	CcSEcCtD
Levonorgestrel—Dyspnoea—Docetaxel—prostate cancer	6.38e-06	0.000115	CcSEcCtD
Levonorgestrel—Somnolence—Docetaxel—prostate cancer	6.37e-06	0.000115	CcSEcCtD
Levonorgestrel—Discomfort—Prednisone—prostate cancer	6.37e-06	0.000115	CcSEcCtD
Levonorgestrel—Eye disorder—Epirubicin—prostate cancer	6.35e-06	0.000114	CcSEcCtD
Levonorgestrel—Hypersensitivity—Etoposide—prostate cancer	6.35e-06	0.000114	CcSEcCtD
Levonorgestrel—Haemoglobin—Doxorubicin—prostate cancer	6.32e-06	0.000114	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Capecitabine—prostate cancer	6.32e-06	0.000114	CcSEcCtD
Levonorgestrel—Cardiac disorder—Epirubicin—prostate cancer	6.31e-06	0.000114	CcSEcCtD
Levonorgestrel—Rhinitis—Doxorubicin—prostate cancer	6.31e-06	0.000113	CcSEcCtD
Levonorgestrel—Dyspepsia—Docetaxel—prostate cancer	6.3e-06	0.000113	CcSEcCtD
Levonorgestrel—Haemorrhage—Doxorubicin—prostate cancer	6.29e-06	0.000113	CcSEcCtD
Levonorgestrel—Insomnia—Capecitabine—prostate cancer	6.27e-06	0.000113	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Doxorubicin—prostate cancer	6.26e-06	0.000113	CcSEcCtD
Levonorgestrel—Pharyngitis—Doxorubicin—prostate cancer	6.24e-06	0.000112	CcSEcCtD
Levonorgestrel—Decreased appetite—Docetaxel—prostate cancer	6.23e-06	0.000112	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Doxorubicin—prostate cancer	6.21e-06	0.000112	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Docetaxel—prostate cancer	6.18e-06	0.000111	CcSEcCtD
Levonorgestrel—Asthenia—Etoposide—prostate cancer	6.18e-06	0.000111	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Doxorubicin—prostate cancer	6.18e-06	0.000111	CcSEcCtD
Levonorgestrel—Dyspnoea—Capecitabine—prostate cancer	6.18e-06	0.000111	CcSEcCtD
Levonorgestrel—Oedema—Prednisone—prostate cancer	6.18e-06	0.000111	CcSEcCtD
Levonorgestrel—Fatigue—Docetaxel—prostate cancer	6.17e-06	0.000111	CcSEcCtD
Levonorgestrel—Urethral disorder—Doxorubicin—prostate cancer	6.17e-06	0.000111	CcSEcCtD
Levonorgestrel—Nausea—Mitoxantrone—prostate cancer	6.15e-06	0.000111	CcSEcCtD
Levonorgestrel—Immune system disorder—Epirubicin—prostate cancer	6.14e-06	0.00011	CcSEcCtD
Levonorgestrel—Infection—Prednisone—prostate cancer	6.14e-06	0.00011	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Epirubicin—prostate cancer	6.13e-06	0.00011	CcSEcCtD
Levonorgestrel—Pain—Docetaxel—prostate cancer	6.12e-06	0.00011	CcSEcCtD
Levonorgestrel—Constipation—Docetaxel—prostate cancer	6.12e-06	0.00011	CcSEcCtD
Levonorgestrel—Dyspepsia—Capecitabine—prostate cancer	6.1e-06	0.00011	CcSEcCtD
Levonorgestrel—Pruritus—Etoposide—prostate cancer	6.1e-06	0.00011	CcSEcCtD
Levonorgestrel—Shock—Prednisone—prostate cancer	6.08e-06	0.000109	CcSEcCtD
Levonorgestrel—Arrhythmia—Epirubicin—prostate cancer	6.07e-06	0.000109	CcSEcCtD
Levonorgestrel—Visual impairment—Doxorubicin—prostate cancer	6.06e-06	0.000109	CcSEcCtD
Levonorgestrel—Nervous system disorder—Prednisone—prostate cancer	6.06e-06	0.000109	CcSEcCtD
Levonorgestrel—Decreased appetite—Capecitabine—prostate cancer	6.03e-06	0.000108	CcSEcCtD
Levonorgestrel—Alopecia—Epirubicin—prostate cancer	6.01e-06	0.000108	CcSEcCtD
Levonorgestrel—Skin disorder—Prednisone—prostate cancer	6e-06	0.000108	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Capecitabine—prostate cancer	5.99e-06	0.000108	CcSEcCtD
Levonorgestrel—Fatigue—Capecitabine—prostate cancer	5.98e-06	0.000108	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Prednisone—prostate cancer	5.97e-06	0.000107	CcSEcCtD
Levonorgestrel—Mental disorder—Epirubicin—prostate cancer	5.96e-06	0.000107	CcSEcCtD
Levonorgestrel—Erythema multiforme—Doxorubicin—prostate cancer	5.95e-06	0.000107	CcSEcCtD
Levonorgestrel—Pain—Capecitabine—prostate cancer	5.93e-06	0.000107	CcSEcCtD
Levonorgestrel—Constipation—Capecitabine—prostate cancer	5.93e-06	0.000107	CcSEcCtD
Levonorgestrel—Malnutrition—Epirubicin—prostate cancer	5.92e-06	0.000106	CcSEcCtD
Levonorgestrel—Erythema—Epirubicin—prostate cancer	5.92e-06	0.000106	CcSEcCtD
Levonorgestrel—Diarrhoea—Etoposide—prostate cancer	5.9e-06	0.000106	CcSEcCtD
Levonorgestrel—Anorexia—Prednisone—prostate cancer	5.89e-06	0.000106	CcSEcCtD
Levonorgestrel—Eye disorder—Doxorubicin—prostate cancer	5.88e-06	0.000106	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Docetaxel—prostate cancer	5.86e-06	0.000105	CcSEcCtD
Levonorgestrel—Cardiac disorder—Doxorubicin—prostate cancer	5.84e-06	0.000105	CcSEcCtD
Levonorgestrel—Flatulence—Epirubicin—prostate cancer	5.83e-06	0.000105	CcSEcCtD
Levonorgestrel—Tension—Epirubicin—prostate cancer	5.81e-06	0.000104	CcSEcCtD
Levonorgestrel—Nervousness—Epirubicin—prostate cancer	5.75e-06	0.000103	CcSEcCtD
Levonorgestrel—Back pain—Epirubicin—prostate cancer	5.72e-06	0.000103	CcSEcCtD
Levonorgestrel—Dizziness—Etoposide—prostate cancer	5.7e-06	0.000103	CcSEcCtD
Levonorgestrel—Muscle spasms—Epirubicin—prostate cancer	5.69e-06	0.000102	CcSEcCtD
Levonorgestrel—Immune system disorder—Doxorubicin—prostate cancer	5.68e-06	0.000102	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Capecitabine—prostate cancer	5.67e-06	0.000102	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Doxorubicin—prostate cancer	5.67e-06	0.000102	CcSEcCtD
Levonorgestrel—Abdominal pain—Docetaxel—prostate cancer	5.66e-06	0.000102	CcSEcCtD
Levonorgestrel—Body temperature increased—Docetaxel—prostate cancer	5.66e-06	0.000102	CcSEcCtD
Levonorgestrel—Hydrocortisone—CYP3A4—prostate cancer	5.63e-06	0.00404	CrCbGaD
Levonorgestrel—Musculoskeletal discomfort—Prednisone—prostate cancer	5.63e-06	0.000101	CcSEcCtD
Levonorgestrel—Arrhythmia—Doxorubicin—prostate cancer	5.62e-06	0.000101	CcSEcCtD
Levonorgestrel—Insomnia—Prednisone—prostate cancer	5.59e-06	0.000101	CcSEcCtD
Levonorgestrel—Alopecia—Doxorubicin—prostate cancer	5.56e-06	0.0001	CcSEcCtD
Levonorgestrel—Mental disorder—Doxorubicin—prostate cancer	5.51e-06	9.92e-05	CcSEcCtD
Levonorgestrel—Urticaria—Capecitabine—prostate cancer	5.51e-06	9.91e-05	CcSEcCtD
Levonorgestrel—Abdominal pain—Capecitabine—prostate cancer	5.48e-06	9.86e-05	CcSEcCtD
Levonorgestrel—Body temperature increased—Capecitabine—prostate cancer	5.48e-06	9.86e-05	CcSEcCtD
Levonorgestrel—Vomiting—Etoposide—prostate cancer	5.48e-06	9.86e-05	CcSEcCtD
Levonorgestrel—Erythema—Doxorubicin—prostate cancer	5.48e-06	9.85e-05	CcSEcCtD
Levonorgestrel—Malnutrition—Doxorubicin—prostate cancer	5.48e-06	9.85e-05	CcSEcCtD
Levonorgestrel—Anaemia—Epirubicin—prostate cancer	5.47e-06	9.84e-05	CcSEcCtD
Levonorgestrel—Dyspepsia—Prednisone—prostate cancer	5.44e-06	9.78e-05	CcSEcCtD
Levonorgestrel—Rash—Etoposide—prostate cancer	5.43e-06	9.78e-05	CcSEcCtD
Levonorgestrel—Dermatitis—Etoposide—prostate cancer	5.43e-06	9.77e-05	CcSEcCtD
Levonorgestrel—Headache—Etoposide—prostate cancer	5.4e-06	9.71e-05	CcSEcCtD
Levonorgestrel—Flatulence—Doxorubicin—prostate cancer	5.4e-06	9.71e-05	CcSEcCtD
Levonorgestrel—Tension—Doxorubicin—prostate cancer	5.37e-06	9.67e-05	CcSEcCtD
Levonorgestrel—Decreased appetite—Prednisone—prostate cancer	5.37e-06	9.66e-05	CcSEcCtD
Levonorgestrel—Fatigue—Prednisone—prostate cancer	5.32e-06	9.58e-05	CcSEcCtD
Levonorgestrel—Nervousness—Doxorubicin—prostate cancer	5.32e-06	9.57e-05	CcSEcCtD
Levonorgestrel—Vertigo—Epirubicin—prostate cancer	5.32e-06	9.57e-05	CcSEcCtD
Levonorgestrel—Syncope—Epirubicin—prostate cancer	5.31e-06	9.55e-05	CcSEcCtD
Levonorgestrel—Back pain—Doxorubicin—prostate cancer	5.3e-06	9.53e-05	CcSEcCtD
Levonorgestrel—Constipation—Prednisone—prostate cancer	5.28e-06	9.5e-05	CcSEcCtD
Levonorgestrel—Hypersensitivity—Docetaxel—prostate cancer	5.28e-06	9.49e-05	CcSEcCtD
Levonorgestrel—Muscle spasms—Doxorubicin—prostate cancer	5.26e-06	9.47e-05	CcSEcCtD
Levonorgestrel—Palpitations—Epirubicin—prostate cancer	5.23e-06	9.41e-05	CcSEcCtD
Levonorgestrel—Loss of consciousness—Epirubicin—prostate cancer	5.2e-06	9.36e-05	CcSEcCtD
Levonorgestrel—Cough—Epirubicin—prostate cancer	5.16e-06	9.29e-05	CcSEcCtD
Levonorgestrel—Asthenia—Docetaxel—prostate cancer	5.14e-06	9.24e-05	CcSEcCtD
Levonorgestrel—Nausea—Etoposide—prostate cancer	5.12e-06	9.21e-05	CcSEcCtD
Levonorgestrel—Hypertension—Epirubicin—prostate cancer	5.11e-06	9.19e-05	CcSEcCtD
Levonorgestrel—Hypersensitivity—Capecitabine—prostate cancer	5.11e-06	9.19e-05	CcSEcCtD
Levonorgestrel—Pruritus—Docetaxel—prostate cancer	5.07e-06	9.12e-05	CcSEcCtD
Levonorgestrel—Anaemia—Doxorubicin—prostate cancer	5.06e-06	9.11e-05	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Prednisone—prostate cancer	5.05e-06	9.09e-05	CcSEcCtD
Levonorgestrel—Chest pain—Epirubicin—prostate cancer	5.04e-06	9.07e-05	CcSEcCtD
Levonorgestrel—Myalgia—Epirubicin—prostate cancer	5.04e-06	9.07e-05	CcSEcCtD
Levonorgestrel—Anxiety—Epirubicin—prostate cancer	5.02e-06	9.03e-05	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5e-06	9e-05	CcSEcCtD
Levonorgestrel—Discomfort—Epirubicin—prostate cancer	4.98e-06	8.96e-05	CcSEcCtD
Levonorgestrel—Asthenia—Capecitabine—prostate cancer	4.97e-06	8.95e-05	CcSEcCtD
Levonorgestrel—Vertigo—Doxorubicin—prostate cancer	4.92e-06	8.85e-05	CcSEcCtD
Levonorgestrel—Syncope—Doxorubicin—prostate cancer	4.91e-06	8.84e-05	CcSEcCtD
Levonorgestrel—Urticaria—Prednisone—prostate cancer	4.91e-06	8.83e-05	CcSEcCtD
Levonorgestrel—Pruritus—Capecitabine—prostate cancer	4.91e-06	8.83e-05	CcSEcCtD
Levonorgestrel—Diarrhoea—Docetaxel—prostate cancer	4.9e-06	8.82e-05	CcSEcCtD
Levonorgestrel—Abdominal pain—Prednisone—prostate cancer	4.88e-06	8.78e-05	CcSEcCtD
Levonorgestrel—Body temperature increased—Prednisone—prostate cancer	4.88e-06	8.78e-05	CcSEcCtD
Levonorgestrel—Palpitations—Doxorubicin—prostate cancer	4.84e-06	8.71e-05	CcSEcCtD
Levonorgestrel—Oedema—Epirubicin—prostate cancer	4.83e-06	8.69e-05	CcSEcCtD
Levonorgestrel—Loss of consciousness—Doxorubicin—prostate cancer	4.81e-06	8.66e-05	CcSEcCtD
Levonorgestrel—Infection—Epirubicin—prostate cancer	4.8e-06	8.63e-05	CcSEcCtD
Levonorgestrel—Cough—Doxorubicin—prostate cancer	4.78e-06	8.6e-05	CcSEcCtD
Levonorgestrel—Shock—Epirubicin—prostate cancer	4.75e-06	8.55e-05	CcSEcCtD
Levonorgestrel—Diarrhoea—Capecitabine—prostate cancer	4.74e-06	8.54e-05	CcSEcCtD
Levonorgestrel—Nervous system disorder—Epirubicin—prostate cancer	4.74e-06	8.52e-05	CcSEcCtD
Levonorgestrel—Dizziness—Docetaxel—prostate cancer	4.74e-06	8.52e-05	CcSEcCtD
Levonorgestrel—Hypertension—Doxorubicin—prostate cancer	4.73e-06	8.51e-05	CcSEcCtD
Levonorgestrel—Skin disorder—Epirubicin—prostate cancer	4.69e-06	8.44e-05	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Epirubicin—prostate cancer	4.67e-06	8.4e-05	CcSEcCtD
Levonorgestrel—Chest pain—Doxorubicin—prostate cancer	4.66e-06	8.39e-05	CcSEcCtD
Levonorgestrel—Myalgia—Doxorubicin—prostate cancer	4.66e-06	8.39e-05	CcSEcCtD
Levonorgestrel—Anxiety—Doxorubicin—prostate cancer	4.65e-06	8.36e-05	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	4.63e-06	8.33e-05	CcSEcCtD
Levonorgestrel—Discomfort—Doxorubicin—prostate cancer	4.61e-06	8.29e-05	CcSEcCtD
Levonorgestrel—Anorexia—Epirubicin—prostate cancer	4.6e-06	8.28e-05	CcSEcCtD
Levonorgestrel—Progesterone—CYP3A4—prostate cancer	4.59e-06	0.00329	CrCbGaD
Levonorgestrel—Dizziness—Capecitabine—prostate cancer	4.58e-06	8.25e-05	CcSEcCtD
Levonorgestrel—Vomiting—Docetaxel—prostate cancer	4.55e-06	8.19e-05	CcSEcCtD
Levonorgestrel—Hypersensitivity—Prednisone—prostate cancer	4.55e-06	8.19e-05	CcSEcCtD
Levonorgestrel—Rash—Docetaxel—prostate cancer	4.52e-06	8.12e-05	CcSEcCtD
Levonorgestrel—Dermatitis—Docetaxel—prostate cancer	4.51e-06	8.12e-05	CcSEcCtD
Levonorgestrel—Headache—Docetaxel—prostate cancer	4.49e-06	8.07e-05	CcSEcCtD
Levonorgestrel—Oedema—Doxorubicin—prostate cancer	4.47e-06	8.04e-05	CcSEcCtD
Levonorgestrel—Infection—Doxorubicin—prostate cancer	4.44e-06	7.99e-05	CcSEcCtD
Levonorgestrel—Asthenia—Prednisone—prostate cancer	4.43e-06	7.97e-05	CcSEcCtD
Levonorgestrel—Vomiting—Capecitabine—prostate cancer	4.41e-06	7.93e-05	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.4e-06	7.92e-05	CcSEcCtD
Levonorgestrel—Shock—Doxorubicin—prostate cancer	4.4e-06	7.91e-05	CcSEcCtD
Levonorgestrel—Nervous system disorder—Doxorubicin—prostate cancer	4.38e-06	7.89e-05	CcSEcCtD
Levonorgestrel—Rash—Capecitabine—prostate cancer	4.37e-06	7.87e-05	CcSEcCtD
Levonorgestrel—Pruritus—Prednisone—prostate cancer	4.37e-06	7.86e-05	CcSEcCtD
Levonorgestrel—Insomnia—Epirubicin—prostate cancer	4.37e-06	7.86e-05	CcSEcCtD
Levonorgestrel—Dermatitis—Capecitabine—prostate cancer	4.37e-06	7.86e-05	CcSEcCtD
Levonorgestrel—Headache—Capecitabine—prostate cancer	4.34e-06	7.82e-05	CcSEcCtD
Levonorgestrel—Skin disorder—Doxorubicin—prostate cancer	4.34e-06	7.81e-05	CcSEcCtD
Levonorgestrel—Testosterone—CYP3A4—prostate cancer	4.34e-06	0.00311	CrCbGaD
Levonorgestrel—Hyperhidrosis—Doxorubicin—prostate cancer	4.32e-06	7.77e-05	CcSEcCtD
Levonorgestrel—Dyspnoea—Epirubicin—prostate cancer	4.31e-06	7.75e-05	CcSEcCtD
Levonorgestrel—Somnolence—Epirubicin—prostate cancer	4.29e-06	7.73e-05	CcSEcCtD
Levonorgestrel—Anorexia—Doxorubicin—prostate cancer	4.26e-06	7.67e-05	CcSEcCtD
Levonorgestrel—Nausea—Docetaxel—prostate cancer	4.25e-06	7.65e-05	CcSEcCtD
Levonorgestrel—Dyspepsia—Epirubicin—prostate cancer	4.25e-06	7.65e-05	CcSEcCtD
Levonorgestrel—Diarrhoea—Prednisone—prostate cancer	4.23e-06	7.6e-05	CcSEcCtD
Levonorgestrel—Decreased appetite—Epirubicin—prostate cancer	4.2e-06	7.55e-05	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Epirubicin—prostate cancer	4.17e-06	7.5e-05	CcSEcCtD
Levonorgestrel—Fatigue—Epirubicin—prostate cancer	4.16e-06	7.49e-05	CcSEcCtD
Levonorgestrel—Pain—Epirubicin—prostate cancer	4.13e-06	7.43e-05	CcSEcCtD
Levonorgestrel—Constipation—Epirubicin—prostate cancer	4.13e-06	7.43e-05	CcSEcCtD
Levonorgestrel—Nausea—Capecitabine—prostate cancer	4.12e-06	7.41e-05	CcSEcCtD
Levonorgestrel—Dizziness—Prednisone—prostate cancer	4.08e-06	7.35e-05	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.07e-06	7.33e-05	CcSEcCtD
Levonorgestrel—Insomnia—Doxorubicin—prostate cancer	4.04e-06	7.27e-05	CcSEcCtD
Levonorgestrel—Dyspnoea—Doxorubicin—prostate cancer	3.98e-06	7.17e-05	CcSEcCtD
Levonorgestrel—Somnolence—Doxorubicin—prostate cancer	3.97e-06	7.15e-05	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Epirubicin—prostate cancer	3.95e-06	7.11e-05	CcSEcCtD
Levonorgestrel—Dyspepsia—Doxorubicin—prostate cancer	3.93e-06	7.08e-05	CcSEcCtD
Levonorgestrel—Vomiting—Prednisone—prostate cancer	3.93e-06	7.07e-05	CcSEcCtD
Levonorgestrel—Rash—Prednisone—prostate cancer	3.89e-06	7.01e-05	CcSEcCtD
Levonorgestrel—Dermatitis—Prednisone—prostate cancer	3.89e-06	7e-05	CcSEcCtD
Levonorgestrel—Decreased appetite—Doxorubicin—prostate cancer	3.89e-06	6.99e-05	CcSEcCtD
Levonorgestrel—Headache—Prednisone—prostate cancer	3.87e-06	6.96e-05	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.86e-06	6.94e-05	CcSEcCtD
Levonorgestrel—Fatigue—Doxorubicin—prostate cancer	3.85e-06	6.93e-05	CcSEcCtD
Levonorgestrel—Urticaria—Epirubicin—prostate cancer	3.84e-06	6.9e-05	CcSEcCtD
Levonorgestrel—Pain—Doxorubicin—prostate cancer	3.82e-06	6.88e-05	CcSEcCtD
Levonorgestrel—Constipation—Doxorubicin—prostate cancer	3.82e-06	6.88e-05	CcSEcCtD
Levonorgestrel—Body temperature increased—Epirubicin—prostate cancer	3.82e-06	6.87e-05	CcSEcCtD
Levonorgestrel—Abdominal pain—Epirubicin—prostate cancer	3.82e-06	6.87e-05	CcSEcCtD
Levonorgestrel—Nausea—Prednisone—prostate cancer	3.67e-06	6.6e-05	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Doxorubicin—prostate cancer	3.65e-06	6.58e-05	CcSEcCtD
Levonorgestrel—Hypersensitivity—Epirubicin—prostate cancer	3.56e-06	6.4e-05	CcSEcCtD
Levonorgestrel—Urticaria—Doxorubicin—prostate cancer	3.55e-06	6.39e-05	CcSEcCtD
Levonorgestrel—Body temperature increased—Doxorubicin—prostate cancer	3.53e-06	6.36e-05	CcSEcCtD
Levonorgestrel—Abdominal pain—Doxorubicin—prostate cancer	3.53e-06	6.36e-05	CcSEcCtD
Levonorgestrel—Asthenia—Epirubicin—prostate cancer	3.47e-06	6.24e-05	CcSEcCtD
Levonorgestrel—Pruritus—Epirubicin—prostate cancer	3.42e-06	6.15e-05	CcSEcCtD
Levonorgestrel—Diarrhoea—Epirubicin—prostate cancer	3.3e-06	5.95e-05	CcSEcCtD
Levonorgestrel—Hypersensitivity—Doxorubicin—prostate cancer	3.29e-06	5.92e-05	CcSEcCtD
Levonorgestrel—Asthenia—Doxorubicin—prostate cancer	3.21e-06	5.77e-05	CcSEcCtD
Levonorgestrel—Dizziness—Epirubicin—prostate cancer	3.19e-06	5.75e-05	CcSEcCtD
Levonorgestrel—Pruritus—Doxorubicin—prostate cancer	3.16e-06	5.69e-05	CcSEcCtD
Levonorgestrel—Vomiting—Epirubicin—prostate cancer	3.07e-06	5.53e-05	CcSEcCtD
Levonorgestrel—Diarrhoea—Doxorubicin—prostate cancer	3.06e-06	5.5e-05	CcSEcCtD
Levonorgestrel—Rash—Epirubicin—prostate cancer	3.05e-06	5.48e-05	CcSEcCtD
Levonorgestrel—Dermatitis—Epirubicin—prostate cancer	3.04e-06	5.47e-05	CcSEcCtD
Levonorgestrel—Headache—Epirubicin—prostate cancer	3.03e-06	5.44e-05	CcSEcCtD
Levonorgestrel—Dizziness—Doxorubicin—prostate cancer	2.96e-06	5.32e-05	CcSEcCtD
Levonorgestrel—Nausea—Epirubicin—prostate cancer	2.87e-06	5.16e-05	CcSEcCtD
Levonorgestrel—Vomiting—Doxorubicin—prostate cancer	2.84e-06	5.11e-05	CcSEcCtD
Levonorgestrel—Rash—Doxorubicin—prostate cancer	2.82e-06	5.07e-05	CcSEcCtD
Levonorgestrel—Dermatitis—Doxorubicin—prostate cancer	2.82e-06	5.07e-05	CcSEcCtD
Levonorgestrel—Headache—Doxorubicin—prostate cancer	2.8e-06	5.04e-05	CcSEcCtD
Levonorgestrel—Nausea—Doxorubicin—prostate cancer	2.65e-06	4.78e-05	CcSEcCtD
Levonorgestrel—AR—Gene Expression—ESR1—prostate cancer	1.54e-06	4.94e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ERBB3—prostate cancer	1.54e-06	4.93e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FGFR2—prostate cancer	1.54e-06	4.93e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PTHLH—prostate cancer	1.51e-06	4.83e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TGFBR1—prostate cancer	1.51e-06	4.83e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—RFK—prostate cancer	1.49e-06	4.79e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTM3—prostate cancer	1.49e-06	4.79e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.49e-06	4.79e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NAGLU—prostate cancer	1.49e-06	4.79e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.49e-06	4.79e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AOX1—prostate cancer	1.49e-06	4.79e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PGAM2—prostate cancer	1.49e-06	4.79e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—RXRA—prostate cancer	1.49e-06	4.77e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AKR1C3—prostate cancer	1.48e-06	4.75e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PRKACB—prostate cancer	1.47e-06	4.73e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TERT—prostate cancer	1.47e-06	4.73e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.45e-06	4.64e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PPP3CA—prostate cancer	1.44e-06	4.61e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—THBS1—prostate cancer	1.44e-06	4.61e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—COMT—prostate cancer	1.43e-06	4.6e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GSTP1—prostate cancer	1.43e-06	4.58e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—ERCC2—prostate cancer	1.42e-06	4.55e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ANXA1—prostate cancer	1.42e-06	4.54e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.41e-06	4.54e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AMACR—prostate cancer	1.41e-06	4.54e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NAT1—prostate cancer	1.41e-06	4.54e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—DEGS1—prostate cancer	1.41e-06	4.54e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.41e-06	4.54e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HIF1A—prostate cancer	1.41e-06	4.52e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ITPR1—prostate cancer	1.4e-06	4.5e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—NR3C1—prostate cancer	1.4e-06	4.48e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PRKCZ—prostate cancer	1.39e-06	4.46e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.38e-06	4.43e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—LEP—prostate cancer	1.38e-06	4.41e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CAV1—prostate cancer	1.36e-06	4.37e-05	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—CREBBP—prostate cancer	1.35e-06	4.33e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.35e-06	4.33e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KDR—prostate cancer	1.35e-06	4.32e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGFR4—prostate cancer	1.34e-06	4.31e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PARP1—prostate cancer	1.34e-06	4.31e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—TYMS—prostate cancer	1.33e-06	4.26e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CALCA—prostate cancer	1.33e-06	4.25e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ESR1—prostate cancer	1.31e-06	4.21e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GSTM1—prostate cancer	1.31e-06	4.21e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PPARA—prostate cancer	1.31e-06	4.2e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCL12—prostate cancer	1.3e-06	4.16e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—LPL—prostate cancer	1.29e-06	4.13e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—BAD—prostate cancer	1.28e-06	4.11e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—MYC—prostate cancer	1.28e-06	4.11e-05	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—SERPINE1—prostate cancer	1.27e-06	4.06e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CYP1A1—prostate cancer	1.24e-06	3.99e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—APC—prostate cancer	1.24e-06	3.98e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CG—prostate cancer	1.24e-06	3.98e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ERCC2—prostate cancer	1.23e-06	3.95e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EGF—prostate cancer	1.23e-06	3.94e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IRS1—prostate cancer	1.23e-06	3.94e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CASP9—prostate cancer	1.22e-06	3.91e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HPGD—prostate cancer	1.2e-06	3.86e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.2e-06	3.86e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—GSK3B—prostate cancer	1.19e-06	3.82e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NGFR—prostate cancer	1.18e-06	3.79e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PRKCQ—prostate cancer	1.18e-06	3.79e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—INS—prostate cancer	1.18e-06	3.77e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MAP3K7—prostate cancer	1.17e-06	3.75e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—MTHFR—prostate cancer	1.16e-06	3.72e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CREBBP—prostate cancer	1.15e-06	3.69e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IGF1—prostate cancer	1.14e-06	3.65e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PPARA—prostate cancer	1.14e-06	3.65e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.13e-06	3.63e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGF10—prostate cancer	1.12e-06	3.6e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ADRB2—prostate cancer	1.11e-06	3.56e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.1e-06	3.53e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—MTAP—prostate cancer	1.1e-06	3.53e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MAP2K1—prostate cancer	1.1e-06	3.53e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CD—prostate cancer	1.09e-06	3.5e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—VAV3—prostate cancer	1.08e-06	3.48e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SERPINE1—prostate cancer	1.08e-06	3.46e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SRD5A1—prostate cancer	1.07e-06	3.44e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SULT1E1—prostate cancer	1.07e-06	3.44e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CAV1—prostate cancer	1.07e-06	3.43e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TGFBR2—prostate cancer	1.07e-06	3.43e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ITPR1—prostate cancer	1.05e-06	3.37e-05	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—MYC—prostate cancer	1.05e-06	3.37e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FGF2—prostate cancer	1.05e-06	3.35e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—CREBBP—prostate cancer	1.04e-06	3.33e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NOS3—prostate cancer	1.03e-06	3.31e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HSD17B3—prostate cancer	1.02e-06	3.28e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ACSL4—prostate cancer	1.02e-06	3.28e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.02e-06	3.28e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IGF1R—prostate cancer	1.01e-06	3.22e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—JAK2—prostate cancer	1e-06	3.21e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ARG2—prostate cancer	9.8e-07	3.14e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PHGDH—prostate cancer	9.8e-07	3.14e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—UMPS—prostate cancer	9.8e-07	3.14e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MDM2—prostate cancer	9.78e-07	3.14e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—SERPINE1—prostate cancer	9.75e-07	3.13e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CG—prostate cancer	9.74e-07	3.12e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ERBB2—prostate cancer	9.64e-07	3.09e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—LPL—prostate cancer	9.64e-07	3.09e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—LDHB—prostate cancer	9.61e-07	3.08e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PDGFRB—prostate cancer	9.55e-07	3.06e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CB—prostate cancer	9.52e-07	3.05e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP3A5—prostate cancer	9.44e-07	3.03e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ITGB3—prostate cancer	9.31e-07	2.99e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—INS—prostate cancer	9.22e-07	2.96e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CXCL8—prostate cancer	9.15e-07	2.93e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—TCN2—prostate cancer	9.11e-07	2.92e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PDHA1—prostate cancer	9.11e-07	2.92e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—UCP3—prostate cancer	9.11e-07	2.92e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTA3—prostate cancer	9.11e-07	2.92e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CREBBP—prostate cancer	9.03e-07	2.9e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ERBB3—prostate cancer	9.03e-07	2.9e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGFR2—prostate cancer	9.01e-07	2.89e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CDKN1B—prostate cancer	8.93e-07	2.86e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CASP3—prostate cancer	8.75e-07	2.81e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL2—prostate cancer	8.74e-07	2.8e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLC22A3—prostate cancer	8.69e-07	2.79e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HSD3B1—prostate cancer	8.69e-07	2.79e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TERT—prostate cancer	8.65e-07	2.78e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CD—prostate cancer	8.56e-07	2.75e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CCND1—prostate cancer	8.52e-07	2.73e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CTNNB1—prostate cancer	8.44e-07	2.71e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTA4—prostate cancer	8.34e-07	2.67e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—TBXAS1—prostate cancer	8.34e-07	2.67e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HIF1A—prostate cancer	8.27e-07	2.65e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MMP9—prostate cancer	8.27e-07	2.65e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CDKN1A—prostate cancer	8.24e-07	2.64e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PTEN—prostate cancer	8.22e-07	2.64e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTA2—prostate cancer	8.12e-07	2.61e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—NOS3—prostate cancer	8.08e-07	2.59e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—LEP—prostate cancer	8.08e-07	2.59e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ABCG5—prostate cancer	8.02e-07	2.57e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SULT1A1—prostate cancer	8.02e-07	2.57e-05	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—MYC—prostate cancer	8.01e-07	2.57e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CAV1—prostate cancer	8e-07	2.57e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KDR—prostate cancer	7.91e-07	2.54e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EP300—prostate cancer	7.84e-07	2.52e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTA1—prostate cancer	7.84e-07	2.51e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HSD3B2—prostate cancer	7.75e-07	2.49e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NAT2—prostate cancer	7.75e-07	2.49e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTO1—prostate cancer	7.75e-07	2.49e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SRC—prostate cancer	7.63e-07	2.45e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—BAD—prostate cancer	7.53e-07	2.41e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CB—prostate cancer	7.46e-07	2.39e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—LRP2—prostate cancer	7.43e-07	2.38e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PLCB2—prostate cancer	7.43e-07	2.38e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP2C18—prostate cancer	7.43e-07	2.38e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—VEGFA—prostate cancer	7.43e-07	2.38e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PTGS2—prostate cancer	7.39e-07	2.37e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—STAT3—prostate cancer	7.36e-07	2.36e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—APC—prostate cancer	7.29e-07	2.34e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CG—prostate cancer	7.29e-07	2.34e-05	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—AKT1—prostate cancer	7.29e-07	2.34e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—P4HB—prostate cancer	7.29e-07	2.34e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EGF—prostate cancer	7.21e-07	2.31e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IRS1—prostate cancer	7.21e-07	2.31e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLC22A1—prostate cancer	7.09e-07	2.27e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—GSK3B—prostate cancer	7e-07	2.24e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SULT2A1—prostate cancer	6.91e-07	2.22e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—INS—prostate cancer	6.9e-07	2.21e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MYC—prostate cancer	6.83e-07	2.19e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TGFB1—prostate cancer	6.82e-07	2.19e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—MED12—prostate cancer	6.8e-07	2.18e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CREBBP—prostate cancer	6.76e-07	2.17e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GNG5—prostate cancer	6.74e-07	2.16e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EGFR—prostate cancer	6.69e-07	2.14e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IGF1—prostate cancer	6.67e-07	2.14e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NCOA3—prostate cancer	6.49e-07	2.08e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MAP2K1—prostate cancer	6.45e-07	2.07e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PTEN—prostate cancer	6.45e-07	2.07e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CD—prostate cancer	6.41e-07	2.06e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SERPINE1—prostate cancer	6.34e-07	2.03e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KRAS—prostate cancer	6.32e-07	2.03e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HPGDS—prostate cancer	6.2e-07	1.99e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—MYC—prostate cancer	6.17e-07	1.98e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP2C19—prostate cancer	6.16e-07	1.97e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—EP300—prostate cancer	6.15e-07	1.97e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGF2—prostate cancer	6.14e-07	1.97e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NOS3—prostate cancer	6.05e-07	1.94e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTT1—prostate cancer	6.01e-07	1.93e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ACHE—prostate cancer	6.01e-07	1.93e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP2A6—prostate cancer	5.94e-07	1.91e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—JAK2—prostate cancer	5.88e-07	1.89e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CA—prostate cancer	5.8e-07	1.86e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AKR1C3—prostate cancer	5.78e-07	1.85e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PRKACB—prostate cancer	5.75e-07	1.84e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MDM2—prostate cancer	5.74e-07	1.84e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP17A1—prostate cancer	5.69e-07	1.82e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ERBB2—prostate cancer	5.66e-07	1.82e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TP53—prostate cancer	5.61e-07	1.8e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CB—prostate cancer	5.59e-07	1.79e-05	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—AKT1—prostate cancer	5.55e-07	1.78e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NCOA2—prostate cancer	5.42e-07	1.74e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCL8—prostate cancer	5.37e-07	1.72e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CDKN1B—prostate cancer	5.24e-07	1.68e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.17e-07	1.66e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CASP3—prostate cancer	5.14e-07	1.65e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL6—prostate cancer	5.14e-07	1.65e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL2—prostate cancer	5.13e-07	1.65e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.05e-07	1.62e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCND1—prostate cancer	5e-07	1.6e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NQO1—prostate cancer	4.99e-07	1.6e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CTNNB1—prostate cancer	4.95e-07	1.59e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—TH—prostate cancer	4.92e-07	1.58e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MMP9—prostate cancer	4.86e-07	1.56e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CDKN1A—prostate cancer	4.84e-07	1.55e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PTEN—prostate cancer	4.83e-07	1.55e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP1B1—prostate cancer	4.79e-07	1.54e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AKT1—prostate cancer	4.74e-07	1.52e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GGT1—prostate cancer	4.64e-07	1.49e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EP300—prostate cancer	4.6e-07	1.48e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NCOA1—prostate cancer	4.57e-07	1.46e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CA—prostate cancer	4.55e-07	1.46e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.5e-07	1.44e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SRC—prostate cancer	4.48e-07	1.44e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—VEGFA—prostate cancer	4.36e-07	1.4e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—RXRA—prostate cancer	4.34e-07	1.39e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—STAT3—prostate cancer	4.32e-07	1.38e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—AKT1—prostate cancer	4.28e-07	1.37e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—COMT—prostate cancer	4.18e-07	1.34e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTP1—prostate cancer	4.17e-07	1.34e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ITPR1—prostate cancer	4.1e-07	1.31e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MYC—prostate cancer	4.01e-07	1.29e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TGFB1—prostate cancer	4e-07	1.28e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EGFR—prostate cancer	3.92e-07	1.26e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—TYMS—prostate cancer	3.87e-07	1.24e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTM1—prostate cancer	3.83e-07	1.23e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—LPL—prostate cancer	3.76e-07	1.2e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—AKT1—prostate cancer	3.72e-07	1.19e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KRAS—prostate cancer	3.71e-07	1.19e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP1A1—prostate cancer	3.63e-07	1.16e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ERCC2—prostate cancer	3.6e-07	1.15e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CA—prostate cancer	3.41e-07	1.09e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—MTHFR—prostate cancer	3.38e-07	1.08e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PPARA—prostate cancer	3.32e-07	1.06e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TP53—prostate cancer	3.29e-07	1.06e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CAV1—prostate cancer	3.12e-07	1e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL6—prostate cancer	3.02e-07	9.67e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.84e-07	9.12e-06	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AKT1—prostate cancer	2.78e-07	8.92e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—INS—prostate cancer	2.69e-07	8.63e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CREBBP—prostate cancer	2.63e-07	8.45e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.5e-07	8.01e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NOS3—prostate cancer	2.36e-07	7.57e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.18e-07	6.98e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTGS2—prostate cancer	2.16e-07	6.92e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTEN—prostate cancer	1.88e-07	6.04e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—EP300—prostate cancer	1.79e-07	5.76e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.33e-07	4.26e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AKT1—prostate cancer	1.08e-07	3.48e-06	CbGpPWpGaD
